Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 36: 381-383, 1990;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perdrisot, R.
Right arrow Articles by Jallet, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perdrisot, R.
Right arrow Articles by Jallet, P.

Clinical Chemistry, Vol 36, 381-383, Copyright © 1990 by American Association for Clinical Chemistry

Monoclonal immunoradiometric assay of calcitonin improves investigation of familial medullary thyroid carcinoma

R Perdrisot, JC Bigorgne, D Guilloteau and P Jallet
Laboratoire Joliot-Curie, CHRU, Angers, France.

Calcitonin (CT) assay is essential for recognizing medullary thyroid carcinoma (MTC), particularly occult familial MTC. In previous radioimmunoassays of calcitonin, polyclonal antibodies were used. Here we evaluate a new two-site immunoradiometric assay (IRMA) of calcitonin based on use of monoclonal antibodies. We assayed samples from healthy subjects, patients with renal failure, and subjects from families affected by MTC. Basal values for healthy subjects were all less than 10 ng/L. Renal failure is associated with increased basal CT. The CT peak under pentagastrin stimulation in healthy patients was less than 30 ng/L. In familial screening, basal values greater than 10 ng/L or peak values greater than 30 ng/L correspond to subjects with histologically confirmed MCT or micro-MCT. Polyclonal RIA performed in the same subjects failed to detect the moderate increase of CT that IRMA demonstrated. Preliminary results indicate that this new method may allow earlier detection of CT increase and thus improved diagnosis of MCT, particularly in familial screening. Monitoring surgical patients could also be improved by this new assay.


The following articles in journals at HighWire Press have cited this article:


Home page
 Eur J EndocrinolHome page
A. Machens, C. Hofmann, S. Hauptmann, and H. Dralle
Locoregional recurrence and death from medullary thyroid carcinoma in a contemporaneous series: 5-year results
Eur. J. Endocrinol., July 1, 2007; 157(1): 85 - 93.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Machens, U. Schneyer, H.-J. Holzhausen, and H. Dralle
Prospects of Remission in Medullary Thyroid Carcinoma According to Basal Calcitonin Level
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2029 - 2034.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
M. Engelbach, R. Görges, T. Forst, A. Pfützner, R. Dawood, S. Heerdt, T. Kunt, A. Bockisch, and J. Beyer
Improved Diagnostic Methods in the Follow-Up of Medullary Thyroid Carcinoma by Highly Specific Calcitonin Measurements
J. Clin. Endocrinol. Metab., May 1, 2000; 85(5): 1890 - 1894.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Association for Clinical Chemistry.